Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Buthionine sulfoximine + Sirolimus |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Buthionine sulfoximine | BSO | Buthionine sulfoximine (BSO) is a GSH synthesis inhibitor, which results in increased reactive oxygen species, thereby possibly leading to apoptotic and/or cytotoxic activity (PMID: 17991446, PMID: 27092812). | ||
| Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TSC2 loss | Advanced Solid Tumor | sensitive | Buthionine sulfoximine + Sirolimus | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Rapamune (sirolimus) and Buthionine sulfoximine (BSO) resulted in increased production of ROS and cell death in transformed cells deficient for TSC2 in culture, and apoptotic activity and tumor regression in ELT3 cell line xenograft models also deficient for TSC2 (PMID: 27197195). | 27197195 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|